Summary. Febuxostat is a novel non-purine selective inhibitor of xanthine oxidase for the management of hyperuricemia in patients with gout. The ability of febuxostat to decrease serum uric acid ...

Febuxostat is a second-line option for patients with gout who are unable to take allopurinol due to hypersensitivity, intolerance, or lack of efficacy in achieving a target serum uric acid ...

Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to ...

One surprising link Dr. Rothschild highlighted is the strong correlation between CKD and gout. “Chronic kidney disease and gout are more connected than many people realize. In fact, 1 in 4 ...

Tophi can affect any joint, including in the fingers and thumbs. It is a sign of advanced or chronic gout. When tophi affect the small joints of the thumbs and fingers, physical changes and ...

Arthrosi Therapeutics doses first patient in replicate pivotal phase 3 REDUCE 1 trial of lead compound AR882: San Diego Wednesday, March 19, 2025, 11:00 Hrs [IST] Arthrosi Therape ...